

# Premenopausal Equol Excretors Show Plasma Hormone Profiles Associated with Lowered Risk of Breast Cancer<sup>1</sup>

Alison M. Duncan, Barbara E. Merz-Demlow, Xia Xu, William R. Phipps, and Mindy S. Kurzer<sup>2</sup>

Department of Food Science and Nutrition, University of Minnesota, St. Paul, Minnesota 55108 [A. M. D., B. E. M., X. X., M. S. K.], and the Department of Obstetrics and Gynecology, University of Rochester, Rochester, New York 14642 [W. R. P.]

## Abstract

**Increased urinary excretion of equol, a metabolite of the isoflavone daidzein, has been associated with a reduced risk of breast cancer. This risk reduction has generally been presumed to be a consequence of increased isoflavone consumption. However, only 30–40% of the population excretes more than trace amounts of equol, regardless of isoflavone intake. Accordingly, we hypothesized that the observed apparent protective effect of equol is at least in part attributable to hormonal differences between equol excretors and non-excretors, and that these differences are largely independent of isoflavone intake.**

We measured plasma hormone and sex hormone binding globulin (SHBG) concentrations in 14 normally cycling premenopausal women during each of three diet periods in which they consumed differing isoflavone doses (0.15, 1.0, and 2.0 mg/kg of body weight/day) as a component of soy protein isolate. The plasma hormone and SHBG concentrations of equol excretors ( $n = 5$ ) were then compared with those of the non-excretors ( $n = 9$ ). Results showed that even at the lowest dose, urinary equol excretion values for excretors far exceeded those for non-excretors consuming the highest dose. At all doses, equol excretors generally had lower concentrations of estrone, estrone-sulfate, testosterone, androstenedione, dehydroepiandrosterone (DHEA), DHEA-sulfate, and cortisol and higher concentrations of SHBG and midluteal progesterone, a hormonal pattern overall consistent with lowered breast cancer risk. In conclusion, the association of equol excretion and lowered breast cancer risk may largely reflect the tendency of equol excretors to have more favorable hormonal profiles, as opposed to merely reflecting increased isoflavone intake. Equol may be a marker for the presence of colonic

**bacterial enzymatic activity that increases fecal steroid excretion. Alternatively, equol itself, even with very modest isoflavone intake, may exert beneficial effects on the regulation of endogenous hormones.**

## Introduction

Epidemiological studies have shown that breast cancer rates are low in populations that consume soy (1, 2), as well as in subgroups who consume high quantities of soy products within Asian populations (3–6). Because soy is a rich source of the phytoestrogenic isoflavones and isoflavones have been shown to be anticarcinogenic in animal (7) and cell culture studies (8), most researchers assume that the epidemiological findings are attributable to the presence of isoflavones in soy products. Total urinary isoflavones, often used as a surrogate for intake, have been shown to be lower in breast cancer patients than controls (9, 10), and the isoflavone metabolite equol was specifically shown to be inversely associated with breast cancer risk in a recent case control study performed in a population consuming low amounts of isoflavones (11).

Although not present in plant foods, equol is produced in the gastrointestinal tract by bacterial degradation of daidzein, a predominant soy isoflavone (12). Urinary excretion of equol varies up to 800-fold among individuals (13–17), because 60–70% of the population excretes only trace amounts of equol, regardless of isoflavone intake (13, 15, 16, 18). This high variability in urinary equol excretion is presumably attributable to interindividual differences in colonic bacteria. Although most researchers conclude that the association of urinary isoflavone excretion with low breast cancer risk is a result of differences in isoflavone consumption between cases and controls, it is possible that breast cancer cases excrete significantly less equol than controls (11), largely as a result of differences in phytoestrogen metabolism, rather than intake.

Along these lines, we hypothesized that the ability to excrete equol in more than trace amounts *per se* may be associated with a lower breast cancer risk. Given the association between breast cancer risk and plasma hormone concentrations (19, 20), we specifically hypothesized that equol excretors would have hormone profiles more favorable from a breast cancer standpoint when compared with non-excretors consuming identical doses of isoflavones. Using data from a crossover study designed to investigate the hormonal effects of soy isoflavones in normally cycling premenopausal women (21), we tested this hypothesis by comparing plasma hormone concentrations of equol excretors to those of non-excretors who were provided three isoflavone doses.

## Materials and Methods

**Subjects and Experimental Design.** The current study used data from a study reported previously of the hormonal effects of isoflavones in premenopausal women (21). The University of

Received 10/8/99; revised 3/8/00; accepted 3/20/00.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> Supported by NIH Grant CA-66016 and General Clinical Research Center Grant MO1-RR00400 from the National Center for Research Resources.

<sup>2</sup> To whom requests for reprints should be addressed, at Department of Food Science and Nutrition, University of Minnesota, 1334 Eckles Avenue, St. Paul, MN 55108. Phone: (612) 624-9789; Fax: (612) 625-5272; E-mail: mkurzer@tc.umn.edu.

Minnesota Institutional Review Board: Human Subjects Committee approved the study protocol. Potential subjects were selected after a phone questionnaire, interview, and health screen. Exclusionary criteria included vegetarian, high fiber, high soy, or low fat diets; regular consumption of vitamin and mineral supplementation greater than the Recommended Dietary Allowances; athleticism; cigarette smoking; antibiotic or hormone use within 6 months; history of chronic disorders including endocrine or gynecological diseases; benign breast disease; regular use of medication including aspirin; current pregnancy or lactation; irregular menstrual cycles; <90% or >120% ideal body weight; weight change >10 pounds within the previous year or weight change >5 pounds within the previous 2 months; consumption of more than two alcoholic beverages per day; and a history of food allergies. Fourteen subjects completed the entire study. The randomized crossover design included three diet periods of three menstrual cycles and 9 days each, separated by an approximately 3-week washout.

**Experimental Soy Supplement.** Subjects consumed their habitual diets but were provided with detailed dietary instructions to minimize phytoestrogen consumption (21). Their diets were supplemented with three soy protein isolate powders, each similar in macronutrient composition but different in isoflavone concentration (Supro Brand Isolated Soy Protein; Protein Technologies International, St. Louis, MO). The three soy powders provided  $0.15 \pm 0.01$  (control),  $1.01 \pm 0.04$  (low-iso), and  $2.01 \pm 0.03$  (high-iso) mg total isoflavones/kg body weight/day ( $10 \pm 1.1$ ,  $64 \pm 9.2$  and  $128 \pm 16$  mg isoflavones/day, respectively), expressed as unconjugated phytoestrogen units. The proportions of genistein, daidzein, and glycitein in the soy powders averaged 55, 37, and 8%, respectively. The daily nutrient contribution of the soy protein isolates has been described previously (21).

**Study Procedures.** Fasting body weight was obtained in a hospital gown approximately every 7–10 days. Skinfold thicknesses were obtained once at the start of the study and once at the end of each diet period to determine the percentage of body fat, as described previously (21).

For determination of day of ovulation, day of LH<sup>3</sup> surge was determined from home urinary LH testing (OvuQUICK Self-Test; Quidel, San Diego, CA) beginning on day 9 of each menstrual cycle until detection of the surge. Basal body temperature was also taken during diet period one and was continued throughout the study for subjects whose OvuQUICK test results were ambiguous.

Fasting blood was drawn in heparinized tubes every other day beginning 7 days after the LH surge in menstrual cycle 2 and continuing until the end of each diet period. Plasma was separated, ascorbic acid and sodium azide were each added to a final concentration of 0.1%, and aliquots were frozen at  $-20^{\circ}\text{C}$  until analysis.

Twenty-four-h urine collections were performed during the MF phase (days 7–9) of menstrual cycle 4 of each diet period. Urine was collected in plastic containers containing 1 g of ascorbic acid per liter and separated into aliquots after the addition of sodium azide to a final concentration of 0.1%. Aliquots were frozen at  $-20^{\circ}\text{C}$  until analysis.

Food records were obtained for three consecutive days

during the follicular phase (days 7–9) and luteal phase (7–9 days after the LH surge) of every menstrual cycle.

**Analytical Methods.** All plasma samples were analyzed for E<sub>2</sub>, E<sub>1</sub>, E<sub>1</sub>-S, progesterone, LH and FSH. Plasma samples from days 2 to 5 of menstrual cycles 3 and 4 were also analyzed for testosterone, androstenedione, DHEA, DHEA-S, cortisol, insulin, and SHBG. All samples from each subject were analyzed in duplicate in the same batch, along with a plasma pool control, to reduce interassay variability. All hormones were analyzed by RIA techniques, as described elsewhere (21).

Before analysis, three-day urines were thawed and proportionally combined to create a pooled sample. Urine was analyzed for equol concentration using ion-exchange chromatography followed by gas chromatography-mass spectrometry, as described previously (15).

Three-day food records were analyzed using Nutritionist IV, Version 4.0 (The Hearst Corporation, San Bruno, CA), and averages were calculated for energy, macronutrients, and dietary fiber.

**Data Analysis.** Day of ovulation was assumed to be the day after the LH surge, as determined by a positive OvuQUICK result. However, if the OvuQUICK results were ambiguous, plasma hormones, urinary LH, and basal body temperature measurements were used as adjuncts, allowing for precise identification of the day of ovulation by a reproductive endocrinologist (W. R. P.). Follicular phase length was defined as day 1 of the menstrual cycle through the day of ovulation. Luteal phase length was defined as the remainder of the cycle, through the day before the next menses.

For reproductive hormone analyses, the menstrual cycle was divided into four phases, each reflecting a distinct hormone milieu: EF (days 2 and 4), MF (days 7 and 9), PO (ovulation -3, ovulation -1, and ovulation +1) and ML (ovulation +5, ovulation +7, and ovulation +9). For subjects whose blood was not drawn on the days used in the phase definitions, interpolation using values obtained on the surrounding days was used to determine the values for the data analyses.

**Statistical Analysis.** Although there are no established levels of equol excretion that separate equol excretors from non-excretors, subjects fell clearly into the two categories (Table 1), particularly at the higher levels of isoflavone consumption.

Comparisons between equol excretors and non-excretors were made within each of the three diets, using unpaired, two-tailed Student's *t* tests (SAS Institute, Inc., Cary, NC; Ref. 22). Because of the unequal variance between menstrual cycle phases, plasma hormone comparisons were made within each phase separately, for each of the three diets. Effects of isoflavone consumption on urinary equol, genistein, and daidzein were evaluated using repeated measures ANOVA, controlling for subject and diet. The interactions between equol excretion status and diet were evaluated to determine whether the effects of diet significantly differed between equol excretors and non-excretors. Because of unequal variance and nonnormality, urinary genistein and daidzein data were log-transformed and are presented as the geometric mean and 95% confidence interval.  $P < 0.05$  is considered significant.

## Results

Urinary isoflavone results are presented in Table 1. Urinary daidzein and genistein significantly increased as isoflavone dose increased, and there were no significant differences between equol excretors and non-excretors for any of the diet periods. As expected, equol excretors excreted substantially greater amounts of equol during all three diet periods, when

<sup>3</sup> The abbreviations used are: LH, luteinizing hormone; FSH, follicle stimulating hormone; DHEA, dehydroepiandrosterone; DHEA-S, DHEA sulfate; E<sub>2</sub>, estradiol; E<sub>1</sub>, estrone; E<sub>1</sub>-S, estrone sulfate; SHBG, sex hormone binding globulin; EF, early follicular; MF, midfollicular; PO periovulatory; ML, midluteal.

Table 1 Urinary isoflavone excretion (nmol/24 h)<sup>a</sup>

	Control (n = 13 <sup>b</sup> )	Low-iso (n = 13 <sup>c</sup> )	High-iso (n = 14)
Daidzein <sup>d</sup>			
Equol excretors	810* (5.5%) (2.83,2319)	4402† (4.7%) (2293,8452)	8250‡ (4.4%) (6176,11021)
Equol non-excretors	1214* (8.3%) (914,1613)	6053† (6.5%) (4403,8321)	10485‡ (5.6%) (7552,14557)
Genistein <sup>d</sup>			
Equol excretors	1097* (5.4%) (523,2301)	7647† (5.9%) (6120,9554)	15438‡ (5.9%) (10380,22961)
Equol non-excretors	965* (4.7%) (755,1234)	6317† (4.8%) (4133,9656)	13969‡ (5.4%) (10045,19426)
Equol <sup>e</sup>			
Equol excretors	996 ± 364* (454–2402)	11125 ± 440† (10099–12243)	17743 ± 3509‡ (9749–30811)
Equol non-excretors	56.2 ± 9.7 (24–60)	58.3 ± 10.2 (34–131)	76.1 ± 8.7 (24–109)

<sup>a</sup> Values within rows with different symbols(\*,†,‡) are significantly different ( $P < 0.05$ ).

<sup>b</sup> One subject did not collect urine at the end of the control diet period.

<sup>c</sup> One subject used antibiotics at the end of the low-iso diet period; therefore, her data were excluded.

<sup>d</sup> Data were log-transformed because of unequal variance and nonnormality. Values are presented as geometric mean (% dose), with 95% confidence intervals in parentheses.

<sup>e</sup> Mean ± SE, with the range in parentheses.

compared with non-excretors. As isoflavone dose increased, urinary equol increased in a dose-dependent fashion for the equol excretors ( $P = 0.003$ ) but remained relatively constant for the non-excretors ( $P = 0.22$ ).

Subject characteristics and dietary intake data for the low-iso diet period are shown in Table 2. There were no significant differences between equol excretors and non-excretors for body weight, body mass index, percentage of body fat, or consumption of energy, macronutrients, or dietary fiber. Menstrual cycle and phase lengths were not significantly different between equol excretors and non-excretors, although equol excretors did tend to have longer lengths. The same general results were observed during the control and high-iso diet periods (data not shown).

Table 3 shows reproductive hormone concentrations during the low-iso diet period, when isoflavone intake was likely closest to typical intakes in Asia (23, 24). Within specific cycle phases, equol excretors had significantly lower concentrations of  $E_1$  and  $E_1$ -S and significantly higher concentrations of progesterone and FSH, as well as higher progesterone: $E_2$  ratios, when compared with non-excretors. Similar differences were observed during the control and high-iso diet periods, indicating that these differences exist regardless of isoflavone intake. For example, within the EF phase of the control diet, plasma  $E_1$  was  $57.6 \pm 5.1$  and  $85.2 \pm 6.4$  pmol/l ( $P = 0.007$ ), and  $E_1$ -S was  $1.52 \pm 0.3$  and  $2.78 \pm 0.5$  nmol/l ( $P = 0.03$ ), for equol excretors and non-excretors, respectively. Within the EF phase of the high-iso diet, plasma  $E_1$  was  $60.5 \pm 5.4$  and  $83.5 \pm 5.7$  pmol/l ( $P = 0.01$ ), and  $E_1$ -S was  $1.14 \pm 0.2$  and  $3.06 \pm 0.5$  nmol/L ( $P = 0.003$ ), for equol excretors and non-excretors, respectively. Within the ML phase of the control diet, plasma  $E_1$  was  $144.5 \pm 13.1$  and  $181.6 \pm 18.7$  pmol/l ( $P = 0.24$ ),  $E_1$ -S was  $5.87 \pm 1.1$  and  $8.72 \pm 1.8$  nmol/l ( $P = 0.18$ ), and progesterone was  $64.4 \pm 8.8$  and  $39.7 \pm 3.4$  nmol/l ( $P = 0.005$ ), for equol excretors and non-excretors, respectively. Within the ML phase of the high-iso diet, plasma  $E_1$  was  $140.9 \pm 12.3$  and  $177.1 \pm 15.3$  pmol/l ( $P = 0.14$ ),  $E_1$ -S was  $4.81 \pm 1.2$  and  $9.84 \pm 2.2$  nmol/l ( $P = 0.06$ ), and progesterone was  $48.5 \pm 8.1$  and  $39.2 \pm 1.8$  nmol/l ( $P = 0.30$ ), for equol excretors and non-excretors, respectively.

Within the EF phase, equol excretors had significantly lower concentrations of testosterone, androstenedione, DHEA, DHEA-S, and cortisol and higher concentrations of SHBG (Table 4). There were also nonsignificant trends toward decreased prolactin and insulin. The similarity of these compar-

Table 2 Subject characteristics and dietary intake<sup>a</sup>

	Equol excretors (n = 5)	Equol non-excretors (n = 9)	P
Age (yr)	28.6 ± 1.7	25.3 ± 1.6	0.22
Body weight (kg)	62.2 ± 3.5	64.7 ± 2.7	0.59
BMI (kg/m <sup>2</sup> )	22.1 ± 1.1	23.2 ± 0.6	0.40
% body fat <sup>b</sup>	26.7 ± 2.5	28.9 ± 1.6	0.44
MC length (days) <sup>c</sup>	31.2 ± 2.0	28.7 ± 1.3	0.28
FP length (days) <sup>d</sup>	17.4 ± 2.6	16.6 ± 1.3	0.75
LP length (days) <sup>e</sup>	13.9 ± 0.5	12.1 ± 0.7	0.12
Energy (kcal) <sup>f</sup>	2314 ± 100	2266 ± 59	0.66
Protein (g) <sup>f</sup>	116.4 ± 4.7	113.4 ± 2.9	0.57
Carbohydrate (g) <sup>f</sup>	292.9 ± 14.1	301.6 ± 10.1	0.61
Fat (g) <sup>f</sup>	77.5 ± 3.8	71.8 ± 3.1	0.26
Dietary fiber (g) <sup>f</sup>	9.70 ± 0.8	8.45 ± 0.4	0.12

<sup>a</sup> Mean ± SE within the low-iso diet period.

<sup>b</sup> Determined from skinfold thicknesses.

<sup>c</sup> MC, menstrual cycle.

<sup>d</sup> FP, follicular phase.

<sup>e</sup> LP, luteal phase.

<sup>f</sup> Based on seven 3-day food records per subject; includes contributions from the soy powder.

isons among the three diet periods suggests that the hormonal differences between equol excretors and non-excretors exist regardless of isoflavone intake.

MF urinary excretion of  $E_2$  and  $E_1$  were lower in the equol excretors, when compared with non-excretors. During the low-iso diet period, urinary  $E_2$  was  $5.07 \pm 0.73$  and  $6.71 \pm 0.34$  nmol/day for equol excretors and non-excretors, respectively (lsmean ± SE;  $P = 0.04$ ) and urinary  $E_1$  was  $12.8 \pm 2.1$  and  $17.1 \pm 3.0$  nmol/day for equol excretors and non-excretors, respectively (lsmean ± SE;  $P = 0.05$ ). Results were similar during the control and high-iso diet periods (data not shown). There were no significant differences in 13 other urinary estrogen metabolites (15) between equol excretors and non-excretors.

There were no significant interactions between equol excretor status and diet for either the plasma hormones or urinary estrogens during any diet period. In other words, the effects of diet observed previously on plasma hormones (21) and urinary estrogens (15) were similar in equol excretors and non-excretors.

Table 3 Reproductive hormone concentrations during the low-iso diet period<sup>a,b</sup>

	Equol excretors (n = 5)	Equol non-excretors (n = 9)	P
<b>E<sub>2</sub> (pmol/l)</b>			
EF	90.7 ± 14.1	103.4 ± 14.7	0.56
MF	176.9 ± 48.5	157.9 ± 20.2	0.68
PO	402.0 ± 63.1	390.6 ± 29.4	0.86
ML	279.4 ± 45.9	294.8 ± 25.0	0.75
<b>E<sub>1</sub> (pmol/l)</b>			
EF	64.0 ± 6.8*	86.9 ± 6.9†	0.04
MF	104.3 ± 21.8	110.6 ± 10.0	0.77
PO	171.3 ± 24.0	222.3 ± 27.0	0.22
ML	122.1 ± 9.6*	179.8 ± 15.2†	0.004
<b>E<sub>1</sub>-S (nmol/l)</b>			
EF	1.55 ± 0.4*	3.26 ± 0.5†	0.03
MF	4.14 ± 1.6	4.81 ± 0.7	0.67
PO	7.62 ± 2.3	15.7 ± 3.7	0.14
ML	4.88 ± 1.0*	10.7 ± 2.0†	0.02
<b>Progesterone (nmol/l)</b>			
EF	2.23 ± 0.8	2.58 ± 0.6	0.72
MF	1.49 ± 0.3	2.07 ± 0.4	0.27
PO	4.52 ± 1.1	5.47 ± 0.7	0.44
ML	56.9 ± 6.0*	31.5 ± 4.0†	0.002
<b>Progesterone:E<sub>2</sub></b>			
EF	31.0 ± 11.9	27.4 ± 5.1	0.79
MF	12.7 ± 3.3	15.2 ± 1.8	0.48
PO	25.9 ± 15.8	21.9 ± 2.7	0.82
ML	270.9 ± 65.2*	108.4 ± 11.2†	0.04
<b>LH (IU/l)</b>			
EF	5.74 ± 0.5	6.82 ± 1.5	0.51
MF	8.00 ± 1.4	8.91 ± 2.2	0.73
PO	18.5 ± 4.5	19.3 ± 3.1	0.89
ML	6.21 ± 0.4	6.50 ± 1.2	0.82
<b>FSH (IU/l)</b>			
EF	4.13 ± 0.3	4.30 ± 0.3	0.69
MF	3.86 ± 0.4	4.55 ± 0.3	0.13
PO	4.00 ± 0.6	4.03 ± 0.5	0.96
ML	2.67 ± 0.3*	1.87 ± 0.2†	0.04

<sup>a</sup> Mean ± SE within the low-iso diet period.

<sup>b</sup> Values within rows with different symbols(\*,†) are significantly different ( $P < 0.05$ ).

## Discussion

The objective of this study was to test the hypothesis that premenopausal equol excretors have a plasma hormone profile that is associated with lowered breast cancer risk. The hypothesis was supported by our results in that equol excretors had a more favorable profile when compared with non-excretors at all isoflavone doses studied (0.15, 1.0, and 2.0 mg/kg of body weight/day). This suggests that the inverse association observed previously between urinary equol excretion and breast cancer risk (11) may not have been wholly attributable to differences in isoflavone intake between cases and controls, as suggested by Ingram *et al.* (11), but rather to differences associated with the ability to produce equol.

Of the 14 subjects in this study, 36% were equol excretors (5 of 14 subjects), a percentage consistent with previous studies (13, 15, 16, 18). As isoflavone dose increased, equol excretion increased in the equol excretors but remained relatively constant and low in the equol non-excretors, also in agreement with previous work (25).

The large interindividual variability in equol excretion is thought to be attributable to differences in composition of the intestinal flora, because gut microflora play an important role in isoflavone metabolism (26). Supportive of this are studies

Table 4 Plasma hormone concentrations<sup>a,b</sup>

	Equol excretors (n = 5)	Equol non-excretors (n = 9)	P
<b>Testosterone (nmol/l)</b>			
Control	0.70 ± 0.08*	1.04 ± 0.08†	0.01
Low-iso	0.73 ± 0.07*	1.04 ± 0.07†	0.004
High-iso	0.73 ± 0.06*	1.05 ± 0.07†	0.008
<b>Androstenedione (nmol/l)</b>			
Control	4.98 ± 0.5*	6.83 ± 0.5†	0.03
Low-iso	5.48 ± 0.4*	7.09 ± 0.5†	0.04
High-iso	5.72 ± 0.4	7.05 ± 0.5	0.10
<b>DHEA (nmol/l)</b>			
Control	18.9 ± 1.9*	33.0 ± 2.3†	0.0003
Low-iso	20.8 ± 1.9*	34.6 ± 2.8†	0.0004
High-iso	21.7 ± 2.2*	32.9 ± 2.8†	0.01
<b>DHEA-S (nmol/l)</b>			
Control	2795 ± 323*	5550 ± 692†	0.002
Low-iso	2961 ± 442*	5705 ± 657†	0.002
High-iso	2694 ± 291*	5360 ± 622†	0.0007
<b>Cortisol (nmol/l)</b>			
Control	366.7 ± 46.9	450.0 ± 21.7	0.08
Low-iso	408.3 ± 31.7*	503.5 ± 29.0†	0.04
High-iso	367.6 ± 26.3*	459.1 ± 24.7†	0.03
<b>Prolactin (µg/l)</b>			
Control	11.3 ± 1.0	14.7 ± 1.5	0.07
Low-iso	12.6 ± 1.3	15.6 ± 1.8	0.24
High-iso	13.4 ± 2.0	16.2 ± 2.2	0.39
<b>SHBG (nmol/l)</b>			
Control	40.8 ± 3.8*	27.7 ± 2.6†	0.007
Low-iso	38.4 ± 3.9	28.5 ± 2.8	0.05
High-iso	39.2 ± 3.3*	28.1 ± 2.9†	0.02
<b>Insulin (pmol/l)</b>			
Control	48.3 ± 11.4	58.9 ± 12.8	0.58
Low-iso	42.3 ± 5.3	64.8 ± 11.3	0.08
High-iso	39.2 ± 4.8	48.8 ± 6.7	0.33

<sup>a</sup> Mean ± SE; samples taken from days 2 to 5 of menstrual cycles 3 and 4.

<sup>b</sup> Values within rows with different symbols(\*,†) are significantly different ( $P < 0.05$ ).

showing that germ-free rats fed soy do not excrete equol (27, 28). Although it has been reported that diet may promote growth and/or activity of bacterial populations responsible for equol production (16, 17), there were no differences in dietary intake between equol excretors and non-excretors noted in the current study. Other parameters linked to equol excretion status include intestinal transit time and redox level of the intestine (29).

This is the first study to show that equol excretors have hormone profiles associated with lowered risk of breast cancer (19, 20). In general, equol excretors had lower concentrations of E<sub>1</sub>, E<sub>1</sub>-S, androgens, and prolactin and higher concentrations of SHBG and progesterone, as well as trends toward longer menstrual cycle and phase lengths, when compared with equol non-excretors. Decreased estrogen concentrations are hypothesized to be protective against breast cancer (30), and numerous epidemiological studies have reported a positive association between estrogens and breast cancer risk (31–34). Although E<sub>2</sub> did not differ between equol excretors and non-excretors, increased SHBG concentrations have been associated with lower concentrations of free estradiol and decreased breast cancer risk (35, 36). Studies on the relationship between androgens and breast cancer risk have yielded inconsistent and at times apparently conflicting results (37, 38). However, much of this has to do with the fact that women with decreased adrenal androgen concentrations appear to have a genetic predisposition toward premenopausal breast cancer (38). In contrast, both higher

adrenal and ovarian androgen concentrations are associated with an increased risk for postmenopausal breast cancer (38). Specifically, higher concentrations of the adrenal androgens DHEA (39, 40) and DHEA-S (34, 39, 41, 42) have been linked to increased risk for postmenopausal breast cancer. Furthermore, higher concentrations of androgens produced both by the ovary and the adrenal gland, including testosterone (32, 35, 41–43) and androstenedione (35, 42), have been linked to increased risk for both pre- and postmenopausal breast cancer. Increased breast cancer risk has also been associated with decreased concentrations of progesterone (30), presumably in part related to the increased frequency of ovulatory dysfunction in hyperandrogenic women with polycystic ovaries (38). Finally, increased breast cancer risk has also been associated with increased concentrations of prolactin (44) and shorter menstrual cycle length (45).

Notably, differences in both equol excretion and plasma hormone concentrations between equol excretors and non-excretors were detectable in subjects consuming only 10 mg isoflavones/day. This level significantly exceeds the estimated British and American intakes of 1–3 mg/day (46, 47), although it is below the most recent estimated Asian intakes of 25–40 mg/day (23, 24). Very low urinary isoflavone excretion values were reported in the Australian case control study, showing an inverse association between equol excretion and breast cancer (11), suggesting that the study population consumed a typical Western diet, with average daily isoflavone intake less than or near our lowest dose. Thus, differences in plasma hormones between equol excretors and non-excretors may be present even with isoflavone doses consistent with a Western diet.

It should be noted that the Australian case-control study by Ingram *et al.* (11) has a number of limitations, as noted in an editorial by Messina *et al.* (48). These include lack of data on dietary fiber intake (raising a concern about the association between lignan and fiber consumption), lack of markers for completeness of urine collection, high variability in analytical methods, and the inability to measure urinary genistein. Although these limitations may weaken the findings by Ingram *et al.* (11), they do not completely negate their potential significance.

In our study, the hormonal differences noted between equol excretors and non-excretors were similar for all three isoflavone doses. This suggests that these differences were not attributable to a direct effect of equol but rather that the ability to produce equol in more than trace amounts may be a marker for the presence of colonic bacterial enzyme activity that increases fecal steroid excretion. In addition to influencing equol synthesis, intestinal flora play an important role in the metabolism of estrogens and androgens (49, 50). Vegetarian and Oriental women excrete greater quantities of fecal estrogens and have lower plasma estrogen concentrations, when compared with omnivorous women (51–53), presumably because of decreased enterohepatic circulation. Perhaps the intestinal microflora responsible for this effect are found in highest quantities in equol excretors.

An alternative explanation is that the hormonal differences noted between equol excretors and non-excretors were a consequence of the smallest isoflavone dose being enough to alter plasma hormone concentrations in equol excretors. The mechanism(s) by which equol itself might affect the regulation of endogenous hormones in a direction beneficial to breast cancer risk are not clear, although our observations of decreased estrogens and increased SHBG concentrations in the equol excretors are consistent with *in vitro* data showing that equol is a weak inhibitor of aromatase, an enzyme catalyzing estrogen

synthesis (54), and a stimulus for SHBG synthesis in HepG2 liver carcinoma cells (55). Along these lines, there are epidemiological data showing a positive association between urinary equol and plasma SHBG concentrations (56).

In summary, this is the first study to report that equol excretors and non-excretors show different plasma hormone profiles. The differences observed suggest that interindividual variation in isoflavone metabolism, specifically the ability to excrete equol, may mediate the observed protective effect of equol against breast cancer (11). It is of great interest to consider that modification of equol production status may influence plasma hormones in a direction associated with lowered breast cancer risk. It is also important to note that differences in plasma hormones between equol excretors and non-excretors may contribute to the inconsistent results seen in studies examining the hormonal effects of soy isoflavones in premenopausal women. Future studies of isoflavone effects in humans should therefore consider equol production status.

### Acknowledgments

The soy powders were generously donated by Protein Technologies International (St. Louis, MO).

### References

- Adlercreutz, H., Honjo, H., Higashi, A., Fotsis, T., Hämäläinen, E., Hasegawa, T., and Okada, H. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. *Am. J. Clin. Nutr.*, 54: 1093–1100, 1991.
- Persky, V., and Van Horn, L. Epidemiology of soy and cancer: perspectives and directions. *J. Nutr.*, 125: 709S–712S, 1995.
- Nomura, A., Henderson, B. E., and Lee, J. Breast cancer and diet among the Japanese in Hawaii. *Am. J. Clin. Nutr.*, 31: 2020–2025, 1978.
- Hirayama, T. A large cohort study on cancer risks by diet—with special reference to the risk reducing effects of green-yellow vegetable consumption. In: Y. Hayashi, M. Nagao, T. Sugimura, S. Takayama, L. Tomatis, L. W. Wattenberg, and G. N. Wogen (eds.), *Diet, Nutrition and Cancer*, pp. 41–53. Tokyo: Japanese Scientific Society Press, 1986.
- Lee, H. P., Gourley, L., Duffy, S. W., Estève, J., Lee, J., and Day, N. E. Dietary effects on breast cancer risk in Singapore. *Lancet*, 337: 1197–1200, 1991.
- Wu, A. H., Ziegler, R. G., Horn-Ross, P. L., Nomura, A. M. Y., West, D. W., Kolonel, L. N., Rosenthal, J. F., Hoover, R. N., and Pike, M. C. Tofu and risk of breast cancer in Asian-Americans. *Cancer Epidemiol. Biomark. Prev.*, 5: 901–906, 1996.
- Barnes, S. The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. *Breast Cancer Res. Treat.*, 46: 169–179, 1997.
- Molteni, A., Brizio-Molteni, L., and Persky, V. *In vitro* hormonal effects of soybean isoflavones. *J. Nutr.*, 125: 751S–756S, 1995.
- Adlercreutz, C. H. T., Goldin, B. R., Gorbach, S. L., Höckerstedt, K. A. V., Watanabe, S., Hämäläinen, E. K., Markkanen, M. H., Mäkelä, T. H., Wähälä, K. T., Hase, T. A., and Fotsis, T. Soybean phytoestrogen intake and cancer risk. *J. Nutr.*, 125: 757S–770S, 1995.
- Zheng, W., Dai, Q., Custer, L. J., Shu, X.-O., Wen, W.-Q., Jin, F., and Franke, A. A. Urinary excretion of isoflavonoids and the risk of breast cancer. *Cancer Epidemiol. Biomark. Prev.*, 8: 35–40, 1999.
- Ingram, D., Sanders, K., Kolybaba, M., and Lopez, D. Case-control study of phyto-estrogens and breast cancer. *Lancet*, 350: 990–994, 1997.
- Axelsson, M., Sjövall, J., Gustafsson, B. E., and Setchell, K. D. R. Soya—a dietary source of the non-steroidal oestrogen equol in man and animals. *J. Endocrinol.*, 102: 49–56, 1984.
- Kelly, G. E., Nelson, C., Waring, M. A., Joannou, G. E., and Reeder, A. Y. Metabolism of dietary (soya) isoflavones in human urine. *Clin. Chim. Acta*, 223: 9–22, 1993.
- Kelly, G. E., Joannou, G. E., Reeder, A. Y., Nelson, C., and Waring, M. A. The variable metabolic response to dietary isoflavones in humans. *Proc. Soc. Exp. Biol. Med.*, 208: 40–43, 1995.
- Xu, X., Duncan, A. M., Merz, B. E., and Kurzer, M. S. Effects of soy isoflavones on estrogen and phytoestrogen metabolism in premenopausal women. *Cancer Epidemiol. Biomark. Prev.*, 7: 1101–1108, 1998.

16. Lampe, J. W., Karr, S. C., Hutchins, A. M., and Slavin, J. L. Urinary equol excretion with a soy challenge: influence of habitual diet. *Proc. Soc. Exp. Biol. Med.*, *217*: 335–339, 1998.
17. Lampe, J. W., Gustafson, D. R., Hutchins, A. M., Martini, M. C., Li, S., Wähälä, K., Grandits, G. A., Potter, J. D., and Slavin, J. L. Urinary isoflavonoid and lignan excretion on a Western diet: relation to soy, vegetable and fruit intake. *Cancer Epidemiol. Biomark. Prev.*, *9*: 699–707, 1999.
18. Hutchins, A. M., Slavin, J. L., and Lampe, J. W. Urinary isoflavonoid phytoestrogen and lignan excretion after consumption of fermented and unfermented soy products. *J. Am. Diet. Assoc.*, *95*: 545–551, 1995.
19. Bernstein, L., and Ross, R. K. Endogenous hormones and breast cancer risk. *Epidemiol. Rev.*, *15*: 48–65, 1993.
20. Zumoff, B. Hormonal profiles in women with breast cancer. *Obstet. Gynecol. Clin. North Am.*, *21*: 751–772, 1994.
21. Duncan, A. M., Merz, B. E., Xu, X., Nagel, T. C., Phipps, W. R., and Kurzer, M. S. Soy isoflavones exert modest hormonal effects in premenopausal women. *J. Clin. Endocrinol. Metab.*, *84*: 192–197, 1999.
22. SAS Institute, Inc. Statistical Analysis System, Version 6.12. Cary, NC: SAS Institute, 1993.
23. Wakai, K., Egami, I., Kato, K., Kawamura, T., Tamakoshi, A., Lin, Y., Nakayama, T., Wada, M., and Ohno, Y. Dietary intake and sources of isoflavones among Japanese. *Nutr. Cancer*, *33*: 139–145, 1999.
24. Chen, Z., Zheng, W., Custer, L. J., Dai, Q., Shu, X-O., Jin, F., and Franke, A. A. Usual dietary consumption of soy foods and its correlation with the excretion rate of isoflavonoids in overnight urine samples among Chinese women in Shanghai. *Nutr. Cancer*, *33*: 82–87, 1999.
25. Karr, S. C., Lampe, J. W., Hutchins, A. M., and Slavin, J. L. Urinary isoflavonoid excretion in humans is dose dependent at low to moderate levels of soy-protein consumption. *Am. J. Clin. Nutr.*, *66*: 46–51, 1997.
26. Xu, X., Harris, K. S., Wang, H.-J., Murphy, P. A., and Hendrich, S. Bioavailability of soybean isoflavones depends on gut microflora in women. *J. Nutr.*, *125*: 2307–2315, 1995.
27. Axelson, M., and Setchell, K. D. R. Excretion of lignans in rats—evidence for an intestinal bacterial source for this new group of compounds. *FEBS Lett.*, *123*: 337–342, 1981.
28. Rowland, I., Wiseman, H., Sanders, T., Adlercreutz, H., and Bowey, E. Metabolism of oestrogens and phytoestrogens: role of the gut microflora. *Biochem. Soc. Trans.*, *127*: 304–308, 1999.
29. Setchell, K. D. R., Borriello, S. P., Hulme, P., Kirk, D. N., and Axelson, M. Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. *Am. J. Clin. Nutr.*, *40*: 569–578, 1984.
30. Key, T. J. A., and Pike, M. C. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. *Eur. J. Cancer Clin. Oncol.*, *24*: 29–43, 1988.
31. Toniolo, P. G., Levitz, M., Zeleniuch-Jacquotte, A., Banerjee, S., Koenig, K. L., Shore, R. E., Strax, P., and Pasternack, B. S. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. *J. Natl. Cancer Inst.*, *87*: 190–197, 1995.
32. Berrino, F., Muti, P., Micheli, A., Bolelli, G., Krogh, V., Sciacino, R., Pisani, P., Pataco, S., and Secreto, G. Serum sex hormone levels after menopause and subsequent breast cancer. *J. Natl. Cancer Inst.*, *88*: 291–296, 1996.
33. Thomas, H. V., Key, T. J., Allen, D. S., Moore, J. W., Dowsett, M., Fentiman, I. S., and Wang, D. Y. A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey. *Br. J. Cancer*, *76*: 401–405, 1997.
34. Hankinson, S. E., Willet, W. C., Manson, J. E., Colditz, G. A., Hunter, D. J., Spiegelman, D., Barbieri, R. L., and Speizer, F. E. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. *J. Natl. Cancer Inst.*, *90*: 1292–1299, 1998.
35. Adlercreutz, H., Hämäläinen, E., Gorbach, S. L., Goldin, B. R., Woods, M. N., and Dwyer, J. T. Diet and plasma androgens in postmenopausal and omnivorous women and postmenopausal women with breast cancer. *Am. J. Clin. Nutr.*, *49*: 433–442, 1989.
36. Lipworth, L., Adami, H.-O., Trichopoulos, D., Carlström, K., and Mantzoros, C. Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer. *Epidemiology*, *7*: 96–100, 1996.
37. Pasqualini, J. R. Role of androgens in breast cancer. *J. Steroid Biochem. Mol. Biol.*, *45*: 167–172, 1993.
38. Secreto, G., and Zumoff, B. Abnormal production of androgens in women with breast cancer. *Anticancer Res.*, *14*: 2113–2118, 1994.
39. Dorgan, J. F., Stanczyk, F. Z., Longcope, C., Stephenson, H. E., Jr., Chang, L., Miller, R., Franz, C., Falk, R. T., and Kahle, L. Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 $\beta$ ,17 $\beta$ -diol to risk of breast cancer in postmenopausal women. *Cancer Epidemiol. Biomark. Prev.*, *6*: 177–181, 1997.
40. Gordon, G. B., Bush, T. L., Helzlsouer, K. J., Miller, S. R., and Comstock, G. W. Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer. *Cancer Res.*, *50*: 3859–3862, 1990.
41. Secreto, G., Toniolo, P., Berrino, F., Recchione, C., Cavalleri, A., Pisani, P., Totis, A., Fariselli, G., and Di Pietro, S. Serum and urinary androgens and risk of breast cancer in postmenopausal women. *Cancer Res.*, *51*: 2572–2576, 1991.
42. Dorgan, J. F., Longcope, C., Stephenson, H. E., Jr., Falk, R. T., Miller, R., Franz, C., Kahle, L., Campbell, W. S., Tangrea, J. A., and Schatzkin, A. Relations of prediagnostic serum estrogen and androgen levels to breast cancer risk. *Cancer Epidemiol. Biomark. Prev.*, *5*: 533–539, 1996.
43. Secreto, G., Toniolo, P., Pisani, P., Recchione, C., Cavalleri, A., Fariselli, G., Totis, A., Di Pietro, S., and Berrino, F. Androgens and breast cancer in premenopausal women. *Cancer Res.*, *49*: 471–476, 1989.
44. Ingram, D. M., Nottage, E. M., and Roberts, A. N. Prolactin and breast cancer risk. *Med. J. Aust.*, *153*: 469–473, 1990.
45. Olsson, H., Landin-Olsson, M., and Gullberg, B. Retrospective assessment of menstrual cycle length in patients with breast cancer, in patients with benign breast disease, and in women without breast disease. *J. Natl. Cancer Inst.*, *70*: 17–20, 1983.
46. Jones, A. E., Price, K. R., and Fenwick, G. R. Development and application of a high-performance liquid chromatographic method for the analysis of phytoestrogens. *J. Sci. Food Agric.*, *46*: 357–364, 1989.
47. Tham, D. M., Gardner, C. D., and Haskell, W. L. Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. *J. Clin. Endocrinol. Metab.*, *83*: 2223–2235, 1998.
48. Messina, M., Barnes, S., and Setchell, K. D. Phyto-oestrogens and breast cancer. *Lancet*, *350*: 971–972, 1997.
49. Lombardi, P., Goldin, B., Boutin, E., and Gorbach, S. L. Metabolism of androgens and estrogens by human fecal microorganisms. *J. Steroid Biochem.*, *9*: 795–801, 1978.
50. Gorbach, S. L. Estrogens, breast cancer, and intestinal flora. *Rev. Infect. Dis.*, *6*: S85–S90, 1984.
51. Goldin, B. R., Adlercreutz, H., Dwyer, J. T., Swenson, L., Warram, J. H., and Gorbach, S. L. Effect of diet on excretion of estrogens in pre- and postmenopausal women. *Cancer Res.*, *41*: 3771–3773, 1981.
52. Goldin, B. R., Adlercreutz, H., Gorbach, S. L., Warram, J. H., Dwyer, J. T., Swenson, L., and Woods, M. N. Estrogen excretion patterns and plasma levels in vegetarian and omnivorous women. *N. Engl. J. Med.*, *307*: 1542–1547, 1982.
53. Goldin, B. R., Adlercreutz, H., Gorbach, S. L., Woods, M. N., Dwyer, J. T., Conlon, T., Bohn, E., and Gershoff, S. N. The relationship between estrogen levels and diets of Caucasian American and Oriental immigrant women. *Am. J. Clin. Nutr.*, *44*: 945–953, 1986.
54. Adlercreutz, H., Bannwart, C., Wähälä, K., Mäkelä, T., Brunow, G., Hase, T., Arosemä, P. J., Kellis, J. T., Jr., and Vickery, L. E. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. *J. Steroid Biochem. Mol. Biol.*, *44*: 147–153, 1993.
55. Loukovaara, M., Carson, M., Palotie, A., and Adlercreutz, H. Regulation of sex hormone-binding globulin production by isoflavonoids and patterns of isoflavonoid conjugation in HepG2 cell cultures. *Steroids*, *60*: 656–661, 1995.
56. Adlercreutz, H., Höckerstedt, K., Bannwart, C., Bloigu, S., Hämäläinen, E., Fotsis, T., and Ollus, A. Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin (SHBG). *J. Steroid Biochem.*, *27*: 1135–1144, 1987.

## Premenopausal Equol Excretors Show Plasma Hormone Profiles Associated with Lowered Risk of Breast Cancer

Alison M. Duncan, Barbara E. Merz-Demlow, Xia Xu, et al.

*Cancer Epidemiol Biomarkers Prev* 2000;9:581-586.

**Updated version** Access the most recent version of this article at:  
<http://cebp.aacrjournals.org/content/9/6/581>

**Cited articles** This article cites 48 articles, 16 of which you can access for free at:  
<http://cebp.aacrjournals.org/content/9/6/581.full#ref-list-1>

**Citing articles** This article has been cited by 24 HighWire-hosted articles. Access the articles at:  
<http://cebp.aacrjournals.org/content/9/6/581.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cebp.aacrjournals.org/content/9/6/581>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.